Company intelligence / Profile preview
BiSiChem
Seongnam, Gyeonggi-do, South Koreabisichem.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
BiSiChem is a South Korean biotech company founded in 2017 that focuses on the discovery and development of innovative small molecule drugs for cancer, immuno-oncology, autoimmune disorders, neurological conditions such as Parkinson’s disease, and other indications. Its lead programs are preclinical.
- Therapeutic areas
- OncologyCardiovascularImmunologyNeurology
- Modalities
- Small moleculesAntibody-drug conjugates (ADC)
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
Beyond the preview
Go deeper on BiSiChem.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BiSiChem.